All In Biotech

Drug Trial Radar · NCT07931599

A Research Study Investigating How Well Zenagamtide at Lower Dose Levels Lowers Blood Sugar and Body Weight Compared to Semaglutide at Lower Dose Levels in People With Type 2 Diabetes Treated With Metformin, Sodium-Glucose Cotransporter 2 Inhibitors (SGLT2i), or Both

Efficacy and Safety of Zenagamtide s.c. Once Weekly Compared to Semaglutide s.c. Once Weekly at Lower Dose Levels in Participants With Type 2 Diabetes Inadequately Controlled on Metformin, SGLT2i, or Both

Last checked: Nov 19, 2026Latest source record: Nov 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruitingPivotal-lookingPhase 3. Randomized with 1,060 participants. This is a heuristic, not a regulatory label.

Status

Not yet recruiting

Enrollment

1,060

Planned (sponsor's estimate)

Start

Nov 10, 2026

Primary completion

Jul 24, 2028

Study completion Aug 28, 2028

Sponsor

Lead sponsor
Novo Nordisk A/SNovo Nordisk (NVO)
Sponsor type
Industry
First posted
Nov 12, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The study is testing zenagamtide in participants with type 2 diabetes. The purpose of this clinical study is to find out if zenagamtide is safe and effective for treating people who have type 2 diabetes. Participants will either get zenagamtide or semaglutide. Which treatment participants get is decided by chance. Zenagamtide is a new medicine that doctors cannot prescribe yet, but it has been tested in humans before.

Conditions

  • Diabetes Mellitus, Type 2

Interventions

  • ZenagamtideDrug

    Zenagamtide will be administered subcutaneously once weekly.

  • SemaglutideDrug

    Semaglutide will be administered subcutaneously once weekly.

  • Placebo zenagamtideDrug

    Placebo volume-matched to zenagamtide will be administered subcutaneously once weekly.

  • Placebo semaglutideDrug

    Placebo volume-matched to semaglutide will be administered subcutaneously once weekly.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change in glycated haemoglobin (HbA1c)Time frame: From baseline (week 0) to week 52

Locations

152 sites in 16 countries. Site status is shown where the registry gives one.

  • Scripps Whittier Diabetes Inst

    La Jolla, California

  • First Valley Medical Group

    Lancaster, California

  • Headlands Research CTR Lincoln

    Lincoln, California

  • Desert Oasis Hlthcr Med Group

    Palm Springs, California

  • UC Anschutz Medical Campus

    Aurora, Colorado

  • Northeast Research Institute

    Fleming Island, Florida

  • Encore Medical Research LLC

    Hollywood, Florida

  • Northeast Research Institute

    Jacksonville, Florida

  • University of Florida, College of Medicine Jacksonville

    Jacksonville, Florida

  • My Preferred Research

    Miami, Florida

  • New Horizon Research Center

    Miami, Florida

  • Adult Medicine of Lake County, Inc

    Mt. Dora, Florida

  • True Blue Clinical Research

    Tampa, Florida

  • Encore Medical Research of Weston

    Weston, Florida

  • Hope Clin Res & Wellness

    Conyers, Georgia

  • Cedar-Crosse Research Center

    Chicago, Illinois

  • Iowa Diab & Endo Res Center

    West Des Moines, Iowa

  • Alliance for Multispec Res

    Newton, Kansas

  • MedStar Health Research Institute

    Olney, Maryland

  • Endo And Metab Cons

    Rockville, Maryland

  • Elite Clinical Research Center

    Flint, Michigan

  • Diabetes & Endo Specialists Inc

    Chesterfield, Missouri

  • StudyMetrix Research LLC

    City of Saint Peters, Missouri

  • Palm Research Center Inc-Vegas

    Las Vegas, Nevada

  • Southern NH Diabetes and Endo_Nashua

    Nashua, New Hampshire

  • AMC Community Endocrinology

    Albany, New York

  • Southgate Medical Group, LLP

    West Seneca, New York

  • Great Lakes Medical Research

    Westfield, New York

  • PHC Accelacare

    Statesville, North Carolina

  • Diab & Endo Assoc of Stark Co

    Canton, Ohio

  • Tribe Clinical Research LLC

    Greer, South Carolina

  • South Dakota Urban Indian Health

    Sioux Falls, South Dakota

  • Holston Medical Group

    Kingsport, Tennessee

  • Clinical Research Associates

    Nashville, Tennessee

  • Victorium Clinical Research

    Houston, Texas

  • Southwest Clinical Trials

    Houston, Texas

  • Medical Colleagues-Texas LLP

    Katy, Texas

  • Pinnacle Clinical Research

    San Antonio, Texas

  • Northeast Clinical Research of San Antonio

    San Antonio, Texas

  • Diabetes & Endo Treatment Spec

    Sandy City, Utah

Showing 40 of 152 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.